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Parkinson’s disease is the second most common neurodegenerative condition after Alzheimer’s disease. *e number of patients
will rise dramatically due to ageing of the population and possibly also due to environmental issues. It is widely recognised that the
current models of care for people with Parkinson’s disease or a form of atypical parkinsonism lack continuity, are reactive to
problems rather than proactive, and do not adequately support individuals to self-manage. Integrated models of care have been
developed for other chronic conditions, with a range of positive effects. A multidisciplinary team of professionals in the United
Kingdom and the Netherlands, all with a long history of caring for patients with movement disorders, used knowledge of
deficiencies with the current model of care, an understanding of integrated care in chronic disease and the process of logic
modelling, to develop a novel approach to the care of patients with Parkinson’s disease. We propose a new model, termed PRIME
Parkinson (Proactive and Integrated Management and Empowerment in Parkinson’s Disease), which is designed to manage
problems proactively, deliver integrated, multidisciplinary care, and empower patients and their carers. It has five main
components: (1) personalised care management, (2) education and empowerment of patients and carers, (3) empowerment of
healthcare professionals, (4) a population health approach, and (5) support of the previous four components by patient- and
professional-friendly technology. Having mapped the processes required for the success of this initiative, there is now a re-
quirement to assess its effect on health-related and quality of life outcomes as well as determining its cost-effectiveness. In the next
phase of the project, we will implement PRIME Parkinson in selected areas of the United Kingdom and the Netherlands.
1. Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disease after Alzheimer’s disease.*ere is
also a group of conditions that may initially resemble PD and
that are collectively referred to as atypical parkinsonism; this
includes rarer conditions such as multiple system atrophy,
progressive supranuclear palsy, and Lewy body dementia.
*e global prevalence is estimated to have more than
doubled from 2.5 million individuals in 1990 to 6.1 million
individuals in 2016 [1]. Around 0.3% of the population in
industrialized countries have PD, rising to 1% in those aged
over 60 years [2]. Neurological diseases, including PD, are
now the leading cause of disability globally [3]; PD reduces
life expectancy [4], negatively impacts on health-related
quality of life [5], and is associated with an increased fre-
quency of hospital attendance at higher-than-average costs
[6].
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*ere is a growing recognition that current models of
care are not optimised to care for individuals with PD or
atypical parkinsonism (in the remainder of this paper, we
will only refer to models for persons with PD, noting that
many of the proposed solutions will likely also apply to
persons with a form of atypical parkinsonism). *e het-
erogeneity of PD necessitates a highly personalised ap-
proach whereby treatment is tailored based on patients’
clinical phenotype and specific symptoms [7]. Current care
models are plagued by several drawbacks: there is often a
lack of continuity of care; issues are detected late and
managed reactively; care is often not person-centred; and
approaches may not adequately involve patients in deci-
sions around their care [8]. Patients with PD, their relatives
and healthcare professionals have previously identified
several unmet needs amongst this patient group, including
a need for more support to self-manage; a more collabo-
rative approach between the multidisciplinary team and a
single point of access where questions can be answered and
support is given to find a way in the complex healthcare
system [9].
Given the complex nature of PD, allied health in-
volvement from appropriately skilled professionals, is par-
amount. Questionnaire surveys among allied health
professionals, including physiotherapists, occupational
therapists, and speech-language therapists who had treated
patients with PD within the last year, revealed that over 75%
reported a lack of PD-specific expertise [10]. In the same
study, surveys of patients with PD showed that many of
those experiencing problems, which would potentially
benefit from therapy input, were not receiving any relevant
therapy [10]. Suboptimal care appears more common for
patients who are older, have worse cognition, and have
mobility problems [11]. *is highlights the need to improve
awareness of and referral to allied health professionals and to
ensure access to those with specialist expertise.
A further angle to improving care seeks to empower
patients and their carers. *ere is an increasing awareness
that patients who have the knowledge, skills, and confidence
to look after their health and feel empowered to do so have
better health outcomes, including being more likely to adopt
healthy behaviours and attend available screening pro-
grammes, leading to improved mood and reduced rates of
hospitalisation [12]. Amongst a group of patients with PD
who completed the Patient Activation Measure, 42% scored
as either “disengaged and overwhelmed” or “becoming
aware but still struggling” [13], suggesting there is much
scope to improve involvement and empowerment for people
with PD.
A framework on which to base an innovative model of
care was sought in order to gain an understanding of suc-
cessful approaches that have been implemented and tested in
other disease areas. Developed in the 1990s, the Chronic
Care Model (CCM) was an approach which was designed to
improve the care of people with chronic conditions and
change their care from being reactive to acute events to
planned and proactive [14].
Since its development, the philosophy of the CCM had
positive effects on outcomes such as quality of life, functional
disease status, hospitalisation rates, and adherence to
guidelines, when applied to a range of different conditions,
including diabetes, heart failure, chronic obstructive pul-
monary disease, rheumatoid arthritis, and chronic diseases
in general [15]. It can be challenging to deliver effective care
to people with PDwho are often older [16] and also given the
complex and heterogenous nature of this neurological
condition, which encompasses symptoms that span multiple
medical specialisms and multiple morbidities. *ere is,
therefore, potential to improve current care for persons with
PD by incorporating the theoretical approach of the CCM
which emphasises the need to support patients to self-
manage; improve healthcare professionals’ expertise, and
utilize clinical information systems [17, 18]. A previous
research project in Canada has used the “Expanded CCM,”
which combines the framework of the CCM with principles
of population health promotion, to develop the Chronic
Care Model for Neurological Conditions (CCM-NC) [19].
However, as far as we are aware, there has only been one
previous application of the CCM to the population of in-
dividuals with PD, implemented amongst US Veterans [20]
and none within a European setting.
*e aim of this paper is to describe the development
phase of a project setting out to design a new integrated
model of care, termed “PRIME-Parkinson” (Proactive and
Integrated Management and Empowerment in Parkinson’s
Disease), for people with PD.We have chosen to also include
patients with atypical parkinsonian syndromes, rather than
restricting our model to patients with idiopathic PD because
of the many shared healthcare needs of these patient groups,
and also because we acknowledge that there is often diag-
nostic uncertainty, particularly in the early phases of the
disease [21]. Within the context of this study, PD can,
therefore, be assumed to include all forms of Parkinsonism,
unless otherwise specified.
2. Methods
In order to develop our model, we first considered the goals
of healthcare improvement, secondly the deficiencies in
current PD care, and then used the process of logic mod-
elling to design our intervention. *ese stages are described
in further detail below.
2.1. Aims of Healthcare Improvement. *e “Triple Aim”
describes the three overarching goals which should be
pursued in order to achieve improvement in healthcare
systems: a desire to improve population health, improve the
experience of care, whilst reducing the per capita cost of
healthcare [22]. Acknowledging the risks of work-related
stress and burnout, these aims were expanded by Bod-
enheimer and Sinsky to include the goal of improving the
work-life of those who deliver care, thus creating a qua-
druple aim [23]. It was agreed that the new model of care
should aim to reach/achieve all four aspirations described in
the “quadruple aim,” acknowledging that the model would
need to be at least cost neutral, even if not cost saving.
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2.2. Identifying Issues with Current Care. *e process begun
with a face-to-face meeting to discuss the findings of recent
qualitative work exploring the unmet needs of patients with
PD [9], alongside personal experiences of delivering care to
this group, in order to identify key issues with the current
model of care. *ese were collated into a list of six main
issues with current care (“the problems”) and, for each one,
an accompanying statement was written to describe the
collective vision for what would constitute success in this
area (“the challenge”) (Table 1).
2.3. Rationale for Logic Model Development. We used
knowledge of unmet needs of patients with PD combined
with knowledge of the CCM, and its application to other
chronic diseases, to design a model of care for PD. No
specific author guidelines were used for the development
phase. In order to graphically represent the components of
the intervention, together with the theory around how each
component would be expected to elicit change in outcomes,
the process of logic modelling was used. Logic models enable
us to consider the causal relationships between components
of an intervention as well as the barriers and facilitators
which may influence its success, and it enables us to build in
methods of process evaluation to allow us to explain un-
expected outcomes of a complex intervention [24, 25]. Logic
models have been used in the development of a range of
health promotion strategies including interventions to
prevent childhood obesity [26], to prevent and control HIV
[27], and to integrate mental health into management of
chronic disease [28].
Knowledge of the CCM indicated that multiple com-
ponents would need to be incorporated in order to address
all the issues identified with current PD care. Having
multiple components is one feature of a “complex inter-
vention” [29], as defined by theMedical Research Council, in
guidance which was updated last year [30]. It is acknowl-
edged that evaluation of complex interventions can be
challenging [31].
By clearly defining our intervention within the frame-
work of a logic model, it is possible to build in compre-
hensive methods of process evaluation, alongside the
evaluation of the intervention’s effectiveness [24, 32]. *is
approach makes it possible to determine which elements of a
model do or do not work, draw conclusions about how an
intervention might translate to another context, and in the
case of overall ineffectiveness, establish if this is due to the
intervention itself or simply the way in which it was
implemented [24]. We believe we have used a hybrid ap-
proach to intervention development consistent with what
O’Caithan and colleagues refer to as the “theory and evi-
dence-based” approach so that interventions are based on
combining published research evidence and formal theories
(e.g., organisational theories) and “target population-cen-
tred” so that interventions are based on the views and actions
of the people who will use the intervention [33].
2.4. Approach to Logic Model Development. A group of
healthcare specialists with expertise in the care of patients
with movement disorders, including neurologists and ger-
iatricians, alongside therapy, nursing colleagues, and
methodologists, from both a team in the United Kingdom
(UK) (Royal United Hospital, Bath) and a team in the
Netherlands (Radboud University Medical Centre, Nijme-
gen), worked collaboratively to design a novel and integrated
model of care for patients with PD, including those with PD,
atypical Parkinsonian syndromes and those with cognitive
impairment. *e decision to include patients with all forms
of Parkinsonism, with the exception of drug-induced Par-
kinsonism, was taken with the aim of making this care model
as generalizable as possible to the day-to-day clinical practice
of healthcare professionals in the field of movement dis-
orders. Likewise, this model is intended to be applicable to
patients with PD, regardless of their age or stage of disease,
acknowledging that younger patients are likely to have
different needs to those who are older or have additional
frailty or comorbidities.
Having agreed upon the issues with current care, we used
the structure shown in Figure 1 to define the logic model for
each of the six problems shown in Table 1. *is was an
iterative process which entailed a subgroup of individuals,
who had been involved in the project conception individ-
ually mapping out potential strategies for all six problems.
*ese solutions were then compared and refined over a
series of teleconferences, in order to achieve a unified logic
model. Figure 2 shows a simplified version of the logic model
which was developed for one of the six problems: the late
detection and reactive management of issues that arise in
people with PD.
Having carefully mapped out the key strategies which
would be expected to impact on the problems with current
care, we considered the resources required to implement
these changes. *is led to the categorization of the strategies
and activities into the five main components of our proposed
model. *e detailed logic model was presented back to the
whole group at a face-to-face meeting four months after the
process mapping had begun, and following further refine-
ment, consensus was reached on the final logic model. We
describe the main elements of our model and its overall
philosophy below.
3. Results
We have designed a novel model of care for PD that brings
together components from other chronic diseases which
comprises
(1) Personalised care management
(2) Education and empowerment of patients and carers
(3) Empowerment of healthcare professionals
(4) A population health approach
(5) Patient- and professional-friendly technology
*emeans by which these components are delivered will
need to be tailored according to the country and region of
care delivery. However, we propose several key elements
which, together, form the basis of an integrated model of
care for PD described in further detail below. Figure S1
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shows a summary version of the full logic model, containing
these elements. *e description of the components of the
PRIME-Parkinson model is for illustrative purposes; we aim
to publish comprehensive standard operating procedures as
these are developed.
3.1. PersonalizedCareManagement. A central component of
the model is to arrange adequate personalized care man-
agement for every patient. Care management is the col-
laborative approach to organise multidisciplinary care for,
and in close collaboration with, the patient and his near ones
[34]. In the literature, care management and case man-
agement are used interchangeably. Case management,
however, is focused mainly on supporting patients to nav-
igate and organise their care, whereas care management
refers to a broader concept [35]. It includes, alongside the
direct support of patients, the integration of care among
health professionals. In many cases, it is envisaged that a
Parkinson’s nurse will have a central role in care
management.
*e Parkinson’s nurse facilitates collaboration between
all healthcare professionals involved in a patient’s care,
supports patients to self-monitor and self-manage, pro-
vides information to patients and carers, and ensures that
they know how to access the right help at the right time. A
“single point of access” will be available for patients with
PD, as well as supporting anyone else who may have
concerns or questions, such as carers, the general practi-
tioner, community teams, and secondary care; the indi-
vidual who takes the call can triage the enquiry towards the
appropriate multidisciplinary team member, with the as-
sistance of the Parkinson’s nurse as required. *e im-
portance of specialist nurses in caring for people with PD
was acknowledged over 20 years ago in the UK, and they are
recognized to fulfil several different roles, which comple-
ment those of other multidisciplinary team members [36].
*ese include providing practical and emotional support to
patients and their carers; supporting patient education;
coordination of care and acting as a link between the
patient, primary, and secondary care; and lifestyle advice
and goal-setting [36].
*e Parkinson’s nurse adopts a person-centred ap-
proach by formulating a personalized care plan; this
process allows the Parkinson’s nurse to establish what
matters most to each patient and understand their indi-
vidual needs and preferences, including for what their
treatment is delivered. *e Parkinson’s nurse ascertains the
patient’s goals for treatment and assists them in setting
realistic and achievable goals, together with an agreed
action plan to address their goal; this information can be
documented in the care plan and shared with the multi-
disciplinary team who can periodically enter updates and
review whether the goals have been achieved and, if not,
what further assistance could help with this. *is collab-
orative sharing of information amongst the team enables
the Parkinson’s nurse to monitor progress on the action
plan and proactively intervene if required.
Patients with PD travel along their “journey” as the
disease progresses, and their needs change with increasing
motor and nonmotor symptom burden. Personalised care
will be ensured by accounting for PD severity and impact,
especially their risk of acute deterioration and hospital
admission which will allow the Parkinson’s nurse to adjust
their approach accordingly and proactively target those in
the highest risk group. *e aim is to respond to the earliest
sign of deterioration in the patient’s condition, ideally before
they have the need to present to acute services and to in-
stigate timely measures to stabilise the clinical and/or social
situation. In situations in which acute admission is neces-
sary, the Parkinson’s nurse would be informed, enabling
them to support the inpatient team to achieve continuity of
care and aim to minimise the length of stay.
3.2. Education and Empowerment of Patients and Carers.
Patients and their carers will be supported to access relevant
information in a variety of formats, including written and
electronic resources, group education, and peer support
(both one-to-one and group support).
Given the large amount of information available on a
national level, for example, as provided by Parkinson’s UK
[37], the goal will be to deliver personalised education by
ensuring that patients are directed towards the most relevant
information for them, based on their disease stage, priorities,
health skills, and symptom burden and support them in both
access, comprehension and relevance to their personal
circumstances. *e specific needs of carers will be addressed
by offering opportunities for carers to share experiences,
access information about financial and practical support and
learn how to look after their own wellbeing.
Education will focus on common themes such as
managing medication, staying healthy, self-management,
and advance care planning, as well as targeting certain
disease phases/stages (early diagnosis, complex disease
phase). *is will not just ensure understanding, in order to
promote patient participation in decision-making, but also
take a pragmatic approach on what actions patients might
Table 1: Problems with current care model and challenges to be addressed by an integrated model of care.
Problems with current care e challenge is to:
Lack of multidisciplinary collaboration and continuity of care
Issues detected late and managed reactively
Difficult to access healthcare professionals with appropriate expertise in a timely
fashion
Lack of empowerment and involvement for patients and carers
Care not managed close to home
“One size fits all” treatment and focus mostly on motor symptoms
Deliver integrated care and continuity of care
Manage issues early and proactively
Facilitate access to specialised healthcare
professionals
Educate and empower patients and carers
Organise care close to home
Deliver personalised care and “precision” medicine
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consider in being proactive rather than reactive. It is also
critical that efforts to empower patients consider the
changing complex nature of where patients are on their
chronic disease journey. A recent review highlighted the
development of five different attributes; acceptance, coping,
self-management, integration and adjustment [38]. At-
tempts to empower patients may be problematic without
understanding and accounting for these different attributes
and how they are translated into ways of living.
3.3. Empowerment ofHealthcare Professionals. We recognise
a need to educate and upskill healthcare professionals, in-
cluding clinicians and therapists, to ensure that they have
PD-specific expertise [10] and are able to work in this new
model of care by supporting them in multidisciplinary col-
laboration and delivery of personalised care. In addition, we
will ensure that up-to-date guidelines will be made readily
accessible for all healthcare professionals. Furthermore,
development of evidence-based tools and protocols will
standardise the approach to commonly occurring issues,
focusing on the following issues in particular. *ese condi-
tions have been chosen based on the large impact they have on
risk of hospitalisation and mortality [39]:
(i) Prevention of falls and resulting fractures
(ii) Reducing urinary tract infection
(iii) Reducing neuropsychiatric disorders including
delirium, hallucinations, and psychosis
(iv) Reducing mood disorders and anxiety (including
depression)
(v) Reducing pneumonia caused by swallowing issues
(vi) Reducing social and functional decline
An online collaboration platform (see section below on
technology) will allow all health professionals to see at a
glance who is involved in each patient’s care and what
Problem Strategy Activities Outputs
Outcomes 
(short and 
long term) 
Context
Hypotheses, barriers, and facilitators
Intervention
Figure 1: *e logic model structure used to design the intervention.
Activities
PD nurse identifies and 
target patients at highest 
risk of complications
Triage from a single point of 
access (SPA) and signpost
Educational modules
e.g. staying healthy, self-
management, when/how 
to seek help if concerned 
Evidence-based protocols 
for common issues 
Skills to support patients to 
self-manage 
Communication platform to 
coordinate care 
Electronic “dashboard”: 
displaying patient “risk 
score” and summary of 
multidisciplinary team input 
Problem Strategies
Issues 
detected 
too late 
and 
managed 
reactively 
Outcomes 
(long term) 
Improved patient 
and carer 
experience
Improved 
population health
Improved work-life 
of those delivering 
healthcare
Reduced per capita 
cost of healthcare 
Outputs Outcomes 
(short term)
Personalised care 
management
Education & 
empowerment of 
patients/carers
Empowerment of 
healthcare 
professionals
Patient and 
professional-
friendly 
technology
 number of 
contacts with PD 
nurse
Attendance at 
educational 
sessions 
Adherence to 
protocols 
Team members 
are empowered to 
intervene at 
earliest sign of 
deterioration
Frequency of 
communication 
between the team 
Complete, up-to-
date information 
on dashboard 
Complications 
detected at an 
earlier point 
Reduced 
frequency of 
complications and 
crisis admissions 
Patients and carers 
feel empowered to 
self-manage, self
monitor and seek 
help when needed 
-
PD nurses and 
team members 
feel equipped to 
contribute to a 
care management 
approach
1
2
3
4
Quadruple aim 
Figure 2: *e logic model structure was applied to one of the six “problems with current care” in order to show potential strategies and
activities to address the problem, the outputs/process measures, and the anticipated outcomes. *is figure summarizes the content from the
detailed logic model which was developed.
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priorities have been set for each patient’s care. Regular
multidisciplinary team meetings will facilitate discussion of
complex cases and ensure goals of treatment are aligned.
3.4. A Population Health Approach. A central philosophy in
our model is to deliver care according to a population health
approach, which can be defined as: “an approach that entails
both (1) a clinical perspective, focused on delivering care to
groups enrolled in a health system; and (2) a broader per-
spective, focused on the health of all people in a given
geographic area and emphasises multi-sector approaches
and incorporation of nonclinical interventions to address
social determinants of health” [40]. *is means that a col-
laborative group of healthcare professionals in a certain
geographic region feel a responsibility to improve care for all
patients, carers, and other people within their region. Be-
cause of this responsibility, these health-care professionals
will organise and integrate care in the region and deliver
joint services, e.g., information, educational courses or a
helpline, to all patients with PD, carers and the wider
population in the region. *ere is some initial evidence to
suggest that this approach leads to better outcomes, while
overall healthcare spending remains the same [40]. A
population approach will not only consider the upstream
sociocultural determinants, but will also focus on health
inequalities and equitable access to health care. Whilst we
may or may not be able to modify the existing sex-related
differences in PD risk (men being at higher risk) [41], it is
essential that all sections of society access care in relation to
need and not on the basis of age, sex, socioeconomic status,
ethnicity, or other factors [11]. Any new interventions
should address existing inequities rather than widen them
(“intervention generated inequalities”) which may occur if
more educated patients are better able to make use of these
interventions [42].
3.5. Patient and Professional Friendly Technology. We will
provide a platform which can be accessed by all healthcare
professionals involved in a patient’s care, as well as by the
patients themselves, through which to communicate se-
curely and align and coordinate care. *is platform, whilst
not being a substitute for the (electronic) health record, will
give an up-to-date insight into the members of the multi-
disciplinary team involved in a given patient’s care, allocated
actions, and progress on obtaining the goals set out in the
personalised care plan. We envisage the development of a
patient “dashboard” which enables staff to rapidly ascertain a
patient’s risk category, as well as showing all inputs from the
multidisciplinary team. We will also support professionals
with integrated decision support solutions to assist evidence-
based care.We note that several efforts are currently ongoing
to translate abstract plans on the role of technology in the
model into concrete action points.
Some patients may benefit from monitoring their
symptoms in the home environment. We will develop
electronic survey-based monitoring, which was beneficial in
other chronic diseases [43]. Furthermore, monitoring based
on wearable devices can collect relevant information that can
be communicated to a relevant healthcare professional or
carer with a low burden for patients themselves. Whilst not
appropriate for all, some patients may wish to access video
consultation and others may benefit from being directed
towards freely available, approved apps, specific to their
particular needs.We plan to have smaller substudies that will
look at the value of this enhanced digital technology.
Emerging evidence supports this approach. A recent study
demonstrated the value of home sensing devices for early
detection of urinary tract infections in people with dementia
[44].
3.6. Application of the PRIME-Parkinson Model. Table 2
shows a hypothetical case study of a patient with PD and
exemplifies some of the problems which such a patient may
encounter within the existing system. An alternative sce-
nario is then suggested to demonstrate how implementation
of some components of the PRIME model may have led to a
better outcome.
4. Discussion
In the PRIME-Parkinson project, we present a new inte-
grated model for managing PD and the various forms of
atypical Parkinsonism, which incorporates five key
approaches.
Whilst no evidence has yet been gathered on the utility of
PRIME-Parkinson care, as a whole, it draws on previous
research into specific elements of care and attempts to learn
from previous positive and negative findings which relate to
each of the five components of the PRIME-Parkinson model
as well as responding to the challenges that both patients and
professionals express around the delivery of care.
*e first component of the PRIME-Parkinson model is
that of personalised care management. Despite the lack of
evidence to support the benefit of PD nurse specialists on
clinical outcomes or quality of life, their input has a positive
impact on subjective patient wellbeing, as measured with a
global health question [46]. In another small study, which
randomised patients to receive nurse practitioner input
versus usual care, 96.2% of patients felt that provision of
specialist nurses should be an important priority for the
health service [47]. Indeed, guidance from the National
Institute for Health and Care Excellence (NICE) states that
patients need access to monitoring and a point of contact for
support and information, suggesting this may be delivered
by a Parkinson’s nurse [48].
In the PRIME-Parkinson model, the intention is for a
Parkinson’s nurse to take a significant role in care man-
agement. A trial in the United States which randomised PD
patients to PD nurse-led case management, including de-
velopment of a personalised care plan, coordination of care,
and use of communication tools, found improvement in
several PD quality indicators (assessed by review of medical
records and by participant survey), but concluded that work
is needed to determine if this translates into improved
patient-centred outcomes, such as quality of life and de-
pression scores [49]. A randomised controlled trial in which
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the intervention group had access to a PD nurse specialist in
the role of case manager, alongside other interventions,
including regular home visits, a telephone hotline, and in-
dividual treatment plans, did find an improvement in PD-
related quality of life and motor and nonmotor symptoms at
6 months [50].
*e second component of PRIME-Parkinson, namely,
education and empowerment of patients and carers, aims to
provide patients with PD and their carers with information
tailored to their needs [8]. *e Patient Education Pro-
gramme for Parkinson’s Disease (PEPP) is an example of an
intervention designed to address these needs; it consists of
eight sessions delivered by trained healthcare professionals
and draws on cognitive behavioural therapy techniques,
covering topics such as self-monitoring, stress management,
and how to be proactive in seeking out information [51]. In a
randomised controlled trial, the PEPP reduced the burden of
psychosocial problems for carers with a trend towards
improved quality of life for patients [52]. *ese effects were
replicated when the PEPP was evaluated in clinical practice
[51]. We will face the challenges of providing different
education packages for different stages of the disease as well
as making these accessible for different ages, gender, and
socioeconomic and ethnic groups. New technology may be
helpful as animations and videos, if designed appropriately,
may overcome barriers around literacy. A focus on equitable
access to optimum care for all patients with PD and their
family highlights the importance of a population health-
based approach that goes beyond an individualistic medical
model.
A core vision of our model is to deliver personalised,
patient-centred care. Qualitative research, involving PD
patients and their carers, has revealed a desire for these
individuals to be actively involved in the decision-making
process and for their values and preferences to be respected
[8]. A Cochrane review of trials looking at personalised care
planning interventions for a range of chronic conditions
suggests a trend towards a positive effect on psychological
health and ability to self-manage when a collaborative ap-
proach is used to plan care [53]. *e process of a patient and
clinician jointly agreeing goals, along with actions to address
them, is an important aspect of developing a personalised
care plan [53]. Goal-attainment scaling, a means of nu-
merically comparing multiple, individualised outcomes
which are meaningful to patients, has been used in a range of
patient groups including frail, older adults [54]. A goal-
oriented approach had positive effects, on both goal at-
tainment and secondary outcomes, when applied to
Table 2: A hypothetical case study. Scenario 1 illustrates a chain of events resulting in an adverse outcome for a patient with PD. Scenario 2
offers an example of how this scenario could be managed differently with the application of the PRIME-Parkinsonmodel. FRAX refers to the
University of Sheffield fracture risk assessment tool [45].
Case study
Mrs. Ahmed is a 78-year-old lady who has had idiopathic PD for 5 years. She has recently begun to have a few “minor falls” which she has
put down to “getting older.” She has noticed she sometimes feels dizzy when she stands up but doesn’t like to bother her GP about it and
knows it can be very hard to get an appointment. She considers mentioning it to her PD consultant when she next goes to clinic in 6
months’ time but decides she won’t because she believes the dizziness probably doesn’t have anything to do with her Parkinson’s disease.
Scenario 1 (existing care model)
Mrs. Ahmed begins to feel less confident going out and stops going to social activities. While taking the bins out one evening, she has a bad
fall onto a concrete path, landing on her left side.
Her neighbour calls an ambulance and she is taken to hospital, where she is diagnosed with a neck of femur fracture, requiring an operation.
She develops a lower respiratory tract infection and postoperative delirium, which leads to a prolonged stay in the acute hospital, following
which she is transferred to a community hospital for ongoing rehabilitation.
Scenario 2 (PRIME care model)
Remembering that light-headedness was mentioned at a PRIME-Parkinson-delivered information session she had recently attended, Mrs.
Ahmed contacts the single point of access helpline to discuss her concerns about her recent dizzy spells. *is information is logged in the
collaboration platform and relayed to Mrs. Ahmed’s Parkinson’s nurse who telephones her to discuss her symptoms further and discovers
that she has also begun to have a few falls as well as a number of “near misses.” *e Parkinson’s nurse explores the impact which these
symptoms are having on her life; Mrs. Ahmed fears that she may not be able to attend her nephew’s wedding next month due to her
dizziness and poor balance.
Together, they agree a plan of action, with the aim of helping Mrs. Ahmed achieve her goal of attending the wedding:
(i) Blood pressure (BP) and medications are reviewed; the Parkinson’s nurse suggests to the GP that he consider stopping amlodipine
and Mrs. Ahmed is given advise about increasing her fluid intake, with a plan to review BP and symptoms following these changes.
(ii) A referral is made to a physiotherapist, with specialist expertise in PD, who suggests a personalised exercise plan to improve her
strength and balance.
(iii) A referral is made to an occupational therapist (OT), with specialist expertise in PD, who visits her at home and advises some
changes to reduce hazards and organises for some handrails to be installed.
(iv) *e Parkinson’s nurse advises that Mrs. Ahmed organise an eye test at the opticians.
(v) *e Parkinson’s nurse calculates a FRAX score, with PD included as a secondary cause of osteoporosis, and liaises with the GP
regarding the result.
(vi) Mrs. Ahmed is directed to Parkinson’s UK patient information leaflet on “Falls and Parkinson’s,” in case she wishes to read about
further tips to reduce her risk of falling, and is given a leaflet on ways to improve her bone health.
(vii) *ey agree to have a telephone appointment in 2 weeks to review how she is progressing towards her goal.
(viii) *e physiotherapist and OTdocument their input via the collaborative platform so the Parkinson’s nurse is aware of the actions
which have occurred ready for the telephone follow-up.
Parkinson’s Disease 7
cognitive rehabilitation in PD dementia [55] and when
incorporated into a programme of physical and occupational
therapy for PD [56]. A nonrandomised trial in which the
intervention group received assessment at a tertiary centre
and formulation of an individual care plan, in addition to
access to a network of upskilled Allied Health Professionals
(ParkinsonNet), found no effect on the primary endpoint
after correcting for baseline disease severity; however, any
positive treatment effect is likely to have been diluted since
only 73% of the recommendations made by the tertiary team
were implemented in the community, highlighting the
potential benefit of combining such interventions with a care
manager role, to ensure the personalised care plan is fol-
lowed [57].
*e third component of the PRIME-Parkinson model
focuses on empowerment for healthcare professionals.
Given the complex range of symptoms experienced by
patients with PD and the limitations of pharmacotherapy,
the need to involve a range of allied health professionals in
patient care is well-recognised; there has been a move away
from a monodisciplinary approach, in which a clinician
retains overall responsibility for patient care, with occasional
referral to an allied health professional for input, towards a
more integrated approach in which all professionals in-
volved in a patient’s care work collaboratively, keeping the
patient at the centre of all decision-making [58]. An um-
brella review of systematic reviews, looking at integrated
care and its impact on hospitalisation in chronic diseases,
noted that interventions which involved a multidisciplinary
team component were more effective for management of
specific conditions, such as heart failure, than for managing
chronic disease in general, concluding that it is essential for
multidisciplinary team members to have condition-specific
expertise [59]. *e ParkinsonNet strategy, developed in the
Netherlands and first tested in 2004, sought to create a
structure for the upskilling of healthcare professionals in-
volved in caring for patients with PD, initially physiother-
apists and later other allied health professionals [60, 61]. A
cluster randomised controlled trial involving 16 clusters,
randomised to receive ParkinsonNet physiotherapy versus
usual care for 6 months, did not demonstrate a positive effect
on functional status or quality of life, although did show a
reduction in costs [62]. However, only one-third of patients
in the intervention group received ParkinsonNet physio-
therapy, therefore reducing the difference between control
and active groups; additionally, training of physiotherapists
occurred not long before enrolment of patients which may
not have allowed sufficient time to develop specialist ex-
pertise [62]. Whilst the need for multidisciplinary team
input in PD would seem clear, our model emphasizes the
need for these multidisciplinary team members to receive
augmented, PD-specific training and to ensure that input is
coordinated and person-centred.
*e PRIME-Parkinson model aims to use patient and
professional-friendly technology to enhance delivery of
education, promote collaboration between healthcare pro-
fessionals, and facilitate coordination of care. *e Parkin-
sonNet programme has utilised technology, in the form of
online communities of healthcare professionals to facilitate
continuing professional development, as well as commu-
nities of patients who share knowledge and experiences [60].
Giladi et al. describe an interdisciplinary team approach for
PD in Tel Aviv, which is supported by therapists commu-
nicating and consulting electronically, as well as use of
multidisciplinary team teleconferences to plan immediate
interventions for patients approaching crisis [63]. A small
study aiming to deliver person-centred care to underserved
PD patients in Florida, by means of home visits conducted
by movement disorder clinicians, used video recordings of
the visit, uploaded to the patient electronic health record, to
promote discussion of cases at a weekly multidisciplinary
team meeting [64]. A smart phone-based Parkinson’s
Tracker App, developed to support self-management, has
been found to improve medication adherence and patient-
perceived quality of consultation when compared to usual
care in a multicentre randomised controlled trial [65]. App-
based technology is being used in a trial in which patients in
the intervention arm will have access to a tablet-based,
individualised physiotherapy training programme alongside
an existing therapy programme [66]. *is gives a further
example of the way in which technology may support the
delivery of proactive and integrated care and suggests the
potential to investigate the benefit of enhanced technology in
substudies embedded within PRIME-Parkinson.
Whilst some elements of the proposed model have been
trialled before, with varying degrees of success, it is possible
that real benefit will only be seen when the separate com-
ponents are combined to form a truly integrated model of
care. *is hypothesis is supported by a review of systematic
reviews which found that multicomponent interventions for
chronic disease were more effective at reducing hospitali-
zation and length of stay than interventions focusing on only
one intervention [59]. While combining multiple compo-
nents into one model of care, we propose that the exact
combination and balance of each component that a patient
receives should be individualised to them which reflects the
essence of truly personalised care.
*e PRIME-Parkinson model has a number of features
of a complex intervention, as defined by the Medical Re-
search Council [29]: multiple components, whose applica-
tion will be tailored differently according to the patient
profile, as well as the unpredictable way in which these
elements may interact with one another when combined
within the context of clinical practice. Evaluation within the
framework of a logic model, as described here, reflects our
commitments to robust assessment of the effectiveness of
different components of the PRIME-Parkinson care model.
5. Conclusion
A new integratedmodel of care, PRIME-Parkinson, has been
designed for patients with PD, using the framework of a logic
model. *e PRIME-Parkinson model comprises
(1) Personalised care management
(2) Education and empowerment of patients and carers
(3) Empowerment of healthcare professionals
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(4) A population health approach
(5) Patient- and professional-friendly technology
*ere is now a requirement to gather empirical data as to
its effect on health-related and quality of life outcomes, as
well as determining if it is cost-effective. *is will be con-
ducted in the Netherlands by means of an observational
study involving four community hospitals who will receive
the PRIME intervention and comparison data from other
parts of the Netherlands. In the UK, there will be a pilot
randomised controlled trial of PRIME-Parkinson care versus
treatment as usual. Findings across the two countries will be
assessed for triangulation, and if discordant, we will try to
understand differences through our process measures and
parallel qualitative work with patients, carers, and profes-
sionals. We envisage scope to adopt positive findings from
these studies to other chronic neurological diseases.
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